Edition:
India

ITUS Corp (ITUS.OQ)

ITUS.OQ on NASDAQ Stock Exchange Capital Market

3.70USD
18 May 2018
Change (% chg)

$0.10 (+2.78%)
Prev Close
$3.60
Open
$3.68
Day's High
$3.76
Day's Low
$3.65
Volume
18,155
Avg. Vol
119,377
52-wk High
$6.42
52-wk Low
$0.60

Chart for

About

ITUS Corporation is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek cancer detection platform measures a patient's immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that... (more)
No analyst recommendations are available for .

Overall

Beta: -1.11
Market Cap(Mil.): $42.44
Shares Outstanding(Mil.): 15.32
Dividend: --
Yield (%): --

Financials

  ITUS.OQ Industry Sector
P/E (TTM): -- 27.65 24.66
EPS (TTM): -0.64 -- --
ROI: -75.74 9.23 7.22
ROE: -174.62 12.57 12.39

BRIEF-Itus Corp - Co Entered Into An At Market Issuance Sales Agreement With B. Riley FBR, Inc

* ITUS CORP - ‍ON MARCH 27, CO ENTERED INTO AN AT MARKET ISSUANCE SALES AGREEMENT WITH B. RILEY FBR, INC TO CREATE AN AT MARKET EQUITY PROGRAM​

27 Mar 2018

BRIEF-Itus And Serametrix Announce Results Of A Blinded Prostate Cancer Study

* ITUS AND SERAMETRIX ANNOUNCE RESULTS OF A BLINDED PROSTATE CANCER STUDY

27 Mar 2018

BRIEF-Itus Corp Forms Alliance With Serametrix Corp

* ITUS CORPORATION FORMS ALLIANCE WITH SERAMETRIX CORPORATION

05 Mar 2018

BRIEF-Lewis Titterton Reports 6.6 Pct Stake In Itus Corp As Of Feb. 14, 2018

* LEWIS H. TITTERTON REPORTS 6.6 PERCENT STAKE IN ITUS CORP AS OF FEBRUARY 14, 2018 - SEC FILING‍​ Source text (http://bit.ly/2CoeRLH) Further company coverage:

15 Feb 2018

BRIEF-Itus Corporation Terminates At-The-Market Offering

* ‍TERMINATED ITS AT-THE-MARKET EQUITY PROGRAM WITH B. RILEY FBR INC​ Source text for Eikon: Further company coverage:

12 Dec 2017

Earnings vs. Estimates

No consensus analysis data available.